Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 247, Issue 1-2, 2012, Pages 9-15

  Gan, Yan ^a   Liu, Ruolan ^a   Wu, Wei ^b   Bomprezzi, Roberto ^a   Shi, Fu Dong ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

EAE; Flow cytometry; Multiple sclerosis; Natalizumab; PML; VLA 4

Indexed keywords

NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; CELL ISOLATION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; IMMUNOSURVEILLANCE; MONONUCLEAR CELL; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIGENS, CD; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; INTEGRIN ALPHA4; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MICE, SCID; NEUTROPHIL INFILTRATION; PEPTIDE FRAGMENTS;

EID: 84860840134     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.03.011     Document Type: Article

References (38)

1. Andoniou C.E., Andrews D.M., Degli-Esposti M.A. Natural killer cells in viral infection: more than just killers. Immunol. Rev. 2006, 214:239-250.
2. Biogen Idec Medical Information Webpage https://medinfo.biogenidec.com/.
3. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
4. del Pilar Martin M., Cravens P.D., Winger R., Frohman E.M., Racke M.K., Eagar T.N., Zamvil S.S., Weber M.S., Hemmer B., Karandikar N.J., Kleinschmidt-DeMasters B.K., Stuve O. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 2008, 65:1596-1603.
5. Dorshkind K., Pollack S.B., Bosma M.J., Phillips R.A. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (SCID). J. Immunol. 1985, 134:3798-3801.
6. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 1996, 272:50-54.
7. Flodström-Tullberg M., Bryceson Y.T., Shi F.-D., Höglund P., Ljunggren H.-G. Natural killer cells in human autoimmunity. Curr. Opin. Immunol. 2009, 21:634-640.
8. French A.R., Yokoyama W.M. Natural killer cells and viral infections. Curr. Opin. Immunol. 2003, 15:45-51.
9. Gismondi A., Morrone S., Humphries M.J., Piccoli M., Frati L., Santoni A. Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin. J. Immunol. 1991, 146:384-392.
10. Hao J., Liu R., Piao W., Zhou Q., Vollmer T.L., Campagnolo D.I., Xiang R., La Cava A., Van Kaer L., Shi F.-D. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207:1907-1921.
11. Harrer A., Wipfler P., Einhaeupl M., Pilz G., Oppermann K., Hitzl W., Afazel S., Haschke-Becher E., Strasser P., Trinka E., Kraus J. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. J. Neuroimmunol. 2011, 234:148-154.
12. Horwitz D.A., Gray J.D., Ohtsuka K., Hirokawa M., Takahashi T. The immunoregulatory effects of NK cells - the role of TGF-β and implications for autoimmunity. Immunol. Today 1997, 18:538-542.
13. Huang D., Shi F.-D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., He T.T., Weaver J.T., Ljunggren H.-G., Biron C.A., Littman D.R., Ransohoff R.M. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006, 20:896-905.
14. Kappos L., Bates D., Edan G., Eraksoy M., Garcia-Merino A., Grigoriadis N., Hartung H.P., Havrdová E., Hillert J., Hohlfeld R., Kremenchutzky M., Lyon-Caen O., Miller A., Pozzilli C., Ravnborg M., Saida T., Sindic C., Vass K., Clifford D.B., Hauser S., Major E.O., O'Connor P.W., Weiner H.L., Clanet M., Gold R., Hirsch H.H., Radü E.W., Sørensen P.S., King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10:745-758.
15. Kent S.J., Karlik S.J., Cannon C., Hines D.K., Yednock T.A., Fritz L.C., Horner H.C. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 1995, 58:1-10.
16. Khatri B.O., Man S., Giovannoni G., Koo A.P., Lee J.C., Tucky B., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009, 72:402-409.
17. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 2005, 353:369-374.
18. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005, 353:375-381.
19. Liu J.-Q., Carl J.W., Joshi P.S., RayChaudhury A., Pu X.-A., Shi F.-D., Bai X.-F. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:6227-6235.
20. Macías C., Ballester J.M., Hernándeza P. Expression and functional activity of the very late activation antigen-4 molecule on human natural killer cells in different states of activation. Immunology 2000, 100:77-83.
21. Mendel I., Kerlero de Rosbo N., Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 1995, 25:1951-1959.
22. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P.A., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
23. Ogino M., Namie S., Ozono Y., Miyazaki M., Harada T., Kohno S. Expression of VLA-4 on peripheral mononuclear cells in patients on chronic haemodialysis with carpal tunnel syndrome. Nephrol. Dial. Transplant. 1998, 13:3126-3131.
24. Paya C.V., Patick A.K., Leibson P.J., Rodriguez M. Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J. Immunol. 1989, 143:95-102.
25. Polman C.H., O'Connor P.W., Havrdova E.A., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEJM 2006, 354:899-910.
26. Sasaki K., Pardee A.D., Qu Y., Zhao X., Ueda R., Kohanbash G., Bailey L.M., Okada H., Muthuswamy R., Kalinski P., Basse P.H., Falo L.D., Storkus W.J. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J. Immunother. 2009, 32:793-802.
27. Segal B.M. The role of natural killer cells in curbing neuroinflammation. J. Neuroimmunol. 2007, 191:2-7.
28. Shi F.-D., Ransohoff R.M. Nature killer cells in the central nervous system. Nature killer cells 2010, 373-383. Academic Press, Maryland Heights. M.T. Lotze, A.W. Thomson (Eds.).
29. Shi F.-D., Takeda K., Akira S., Sarvetnick N., Ljunggren H.-G. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J. Immunol. 2000, 165:3099-3104.
30. Skarica M., Eckstein C., Whartenby K.A., Calabresi P.A. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J. Neuroimmunol. 2011, 235:70-76.
31. Stüve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006, 59:743-747.
32. Sun J.C., Beike J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:511-628.
33. Takeda K., Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J. Exp. Med. 1993, 177:155-164.
34. Vollmer T.L., Liu R., Price M., Rhodes S., La Cava A., Shi F.-D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 2005, 174:2696-2701.
35. von Andrian U.H., Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med. 2003, 348:68-72.
36. Wipfler P., Oppermann K., Pilz G., Afazel S., Haschke-Becher E., Harrer A., Huemer M., Kunz A., Golaszewski S., Staffen W., Ladurner G., Kraus J. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult. Scler. 2011, 17:16-23.
37. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
38. Zhang B.-N., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.